Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53:

Robert A Mitchell1, Hong Liao, Jason Chesney

  • 1Picower Institute for Medical Research, New York, NY 11030, USA. rmitchell@picower.edu

Insights

Macrophage migration inhibitory factor (MIF) prevents programmed cell death (apoptosis) in macrophages, crucial for innate immunity. This finding reveals a new way to control immune responses in conditions like sepsis.

Area of Science:

  • Immunology
  • Cell Biology
  • Molecular Medicine

Background:

  • Macrophages are key players in innate immunity, producing critical immunoregulatory molecules.
  • Macrophage migration inhibitory factor (MIF) is a secreted product of activated macrophages.
  • Understanding macrophage survival mechanisms is vital for innate immune response modulation.

Purpose of the Study:

  • To investigate the role of MIF in regulating macrophage survival and function.
  • To elucidate the mechanism by which MIF suppresses apoptosis.
  • To explore MIF's impact on innate immunity, particularly in the context of sepsis.

Main Methods:

  • Utilized MIF-deficient (MIF(-/-)) and wild-type mice.
  • Administered endotoxin to induce immune responses.
  • Assessed macrophage viability, apoptosis, proinflammatory function, p53 activity, and cyclooxygenase-2 (Cox-2) expression.

Main Results:

  • MIF(-/-) mice exhibited decreased macrophage viability, reduced proinflammatory function, and increased apoptosis post-endotoxin challenge compared to wild-type.
  • Inhibition of p53 in MIF-deficient macrophages restored proinflammatory function and reduced apoptosis.
  • MIF suppresses p53 activity via an autocrine pathway involving arachidonic acid metabolism and Cox-2 induction.

Conclusions:

  • MIF sustains macrophage survival and function by inhibiting p53-dependent apoptosis.
  • This mechanism highlights MIF's critical role in innate immunity and inflammation, such as in sepsis.
  • Findings suggest novel therapeutic strategies for modulating innate immune responses by targeting MIF and p53 pathways.